Overland Park, KS – Ronawk, a leading biotechnology company, proudly announces the launch of STELLα, a state-of-the-art non-clinical contract research organization (CRO) dedicated to driving innovation in the life sciences industry. The addition of STELLα to Ronawk’s portfolio represents a significant milestone in the company’s growth and expansion, further solidifying its position as a strategic contributor to the region’s growing biotech ecosystem. [Read more…]

The findings of this study suggest that stem cells could have major implications for treating MS and reversing patient disability even after significant progression.

The study, from the Tisch MS Research Center of New York, is the first to link stem cells with a broad array of improvements. Progressive MS patients demonstrated better outcomes in walking speeds, gray matter volume, bladder function, and biomarker indicators.

[Read more…]

BENGALURU, KARNATAKA, INDIA, MAY 04, 2023 – Oncofocus Solutions, a management consulting firm established in 2014 to cater to the business intelligence needs in the Oncology domain, is offering the live demo of Novus AI, its cutting-edge AI-powered conference intelligence platform. [Read more…]

First patient dosed with CK0803 Treg cells for treatment of amyotrophic lateral sclerosis (ALS).

CK0803 is derived from clinical-grade umbilical cord blood units

Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803.

HOUSTON, May 2, 2023 — Cellenkos^® Inc., a clinical stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory cell therapies for treatment of rare inflammatory diseases and autoimmune disorders, announced that it has dosed the first patient in a Phase 1/1b study evaluating CK0803 for treatment of amyotrophic lateral sclerosis (ALS) (under National Clinical Trial registry NCT05695521). [Read more…]

RICHMOND, Virginia — FUJIFILM Wako Chemicals U.S.A., Corporation announces the launch of a ready-to-use small molecule cocktail comprising of Chroman 1, Emricasan, Polyamines, Trans-ISRIB (CEPT Cocktail), a chemical platform for stress-free cell culture and superior survival of induced pluripotent stem cells (iPSCs). CEPT Cocktail is intended for commercial research-use of iPSC applications including disease modeling, organoid generation, drug discovery, toxicology, and pharmacological studies. [Read more…]